NO324452B1 - Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes - Google Patents

Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes Download PDF

Info

Publication number: NO324452B1
Authority: NO; Norway
Prior art keywords: tetrahydrolipstatin; administered; use according; pharmaceutical preparation; per day
Prior art date: 1997-02-05

Application number

NO19993717A

Other languages

English (en)

Norwegian (no)

Other versions

NO993717L (no

NO993717D0 (no

Inventor

Jonathan Brian Hauptman

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-02-05

Filing date

1999-07-30

Publication date

2007-10-22

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21894047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO324452(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1999-07-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

1999-07-30 Publication of NO993717D0 publication Critical patent/NO993717D0/no

1999-10-04 Publication of NO993717L publication Critical patent/NO993717L/no

2007-10-22 Publication of NO324452B1 publication Critical patent/NO324452B1/no

Links

AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 title claims description 27
229960001243 orlistat Drugs 0.000 title claims description 26
AHLBNYSZXLDEJQ-UHFFFAOYSA-N N-formyl-L-leucylester Natural products CCCCCCCCCCCC(OC(=O)C(CC(C)C)NC=O)CC1OC(=O)C1CCCCCC AHLBNYSZXLDEJQ-UHFFFAOYSA-N 0.000 title claims description 25
238000002360 preparation method Methods 0.000 title claims description 3
229940127003 anti-diabetic drug Drugs 0.000 title 1
239000003472 antidiabetic agent Substances 0.000 title 1
208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 12
239000000203 mixture Substances 0.000 claims description 10
239000000825 pharmaceutical preparation Substances 0.000 claims description 10
235000012054 meals Nutrition 0.000 claims description 4
239000002552 dosage form Substances 0.000 claims description 2
239000008183 oral pharmaceutical preparation Substances 0.000 claims 1
239000000902 placebo Substances 0.000 description 9
229940068196 placebo Drugs 0.000 description 9
206010012601 diabetes mellitus Diseases 0.000 description 7
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 6
239000007903 gelatin capsule Substances 0.000 description 6
239000008103 glucose Substances 0.000 description 6
239000008188 pellet Substances 0.000 description 6
238000007410 oral glucose tolerance test Methods 0.000 description 5
230000001771 impaired effect Effects 0.000 description 4
238000000034 method Methods 0.000 description 4
239000000454 talc Substances 0.000 description 4
229910052623 talc Inorganic materials 0.000 description 4
229920000168 Microcrystalline cellulose Polymers 0.000 description 3
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
239000003925 fat Substances 0.000 description 3
238000009472 formulation Methods 0.000 description 3
239000008187 granular material Substances 0.000 description 3
238000005469 granulation Methods 0.000 description 3
230000003179 granulation Effects 0.000 description 3
229940016286 microcrystalline cellulose Drugs 0.000 description 3
235000019813 microcrystalline cellulose Nutrition 0.000 description 3
239000008108 microcrystalline cellulose Substances 0.000 description 3
239000001267 polyvinylpyrrolidone Substances 0.000 description 3
229920000036 polyvinylpyrrolidone Polymers 0.000 description 3
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
239000008213 purified water Substances 0.000 description 3
235000019333 sodium laurylsulphate Nutrition 0.000 description 3
229940079832 sodium starch glycolate Drugs 0.000 description 3
229920003109 sodium starch glycolate Polymers 0.000 description 3
239000008109 sodium starch glycolate Substances 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
229940086609 Lipase inhibitor Drugs 0.000 description 2
230000002496 gastric effect Effects 0.000 description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
239000008101 lactose Substances 0.000 description 2
239000003538 oral antidiabetic agent Substances 0.000 description 2
230000009467 reduction Effects 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
208000002705 Glucose Intolerance Diseases 0.000 description 1
108010023302 HDL Cholesterol Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
208000031226 Hyperlipidaemia Diseases 0.000 description 1
102000004877 Insulin Human genes 0.000 description 1
108090001061 Insulin Proteins 0.000 description 1
108010028554 LDL Cholesterol Proteins 0.000 description 1
208000008589 Obesity Diseases 0.000 description 1
206010033307 Overweight Diseases 0.000 description 1
235000021355 Stearic acid Nutrition 0.000 description 1
206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000037396 body weight Effects 0.000 description 1
239000000872 buffer Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000012876 carrier material Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
239000008298 dragée Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
239000000796 flavoring agent Substances 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
230000002641 glycemic effect Effects 0.000 description 1
229960001375 lactose Drugs 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
235000020824 obesity Nutrition 0.000 description 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
229940127209 oral hypoglycaemic agent Drugs 0.000 description 1
229940125395 oral insulin Drugs 0.000 description 1
229940126701 oral medication Drugs 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
201000009104 prediabetes syndrome Diseases 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000008117 stearic acid Substances 0.000 description 1
239000000126 substance Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1
239000013585 weight reducing agent Substances 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Hematology (AREA)
Endocrinology (AREA)
Organic Chemistry (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

NO19993717A 1997-02-05 1999-07-30 Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes NO324452B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US3738397P	1997-02-05	1997-02-05
PCT/EP1998/000468 WO1998034630A1 (en)	1997-02-05	1998-01-29	Use of gastrointestinal lipase inhibitors

Publications (3)

Publication Number	Publication Date
NO993717D0 NO993717D0 (no)	1999-07-30
NO993717L NO993717L (no)	1999-10-04
NO324452B1 true NO324452B1 (no)	2007-10-22

Family

ID=21894047

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO19993717A NO324452B1 (no)	1997-02-05	1999-07-30	Anvendelse av tetrahydrolipstatin til fremstilling av medikamenter mot diabetes

Country Status (27)

Country	Link
US (1)	US6147108A (de)
EP (1)	EP1017408B1 (de)
JP (1)	JP2001509173A (de)
KR (1)	KR100479968B1 (de)
CN (1)	CN1154505C (de)
AR (1)	AR011106A1 (de)
AT (1)	ATE292975T1 (de)
AU (1)	AU740375B2 (de)
BR (1)	BR9807655A (de)
CA (1)	CA2278854C (de)
CZ (1)	CZ295567B6 (de)
DE (1)	DE69829763T2 (de)
DK (1)	DK1017408T3 (de)
ES (1)	ES2239799T3 (de)
HU (1)	HU230834B1 (de)
ID (1)	ID22650A (de)
IL (1)	IL131007A0 (de)
ME (1)	ME00578A (de)
NO (1)	NO324452B1 (de)
NZ (1)	NZ336755A (de)
PL (1)	PL191222B1 (de)
PT (1)	PT1017408E (de)
RU (1)	RU2201272C2 (de)
TR (1)	TR199901853T2 (de)
WO (1)	WO1998034630A1 (de)
YU (1)	YU34199A (de)
ZA (1)	ZA98753B (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL191222B1 (pl) *	1997-02-05	2006-03-31	Hoffmann La Roche	Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II
AR025609A1 (es)	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones lipidas solidas
AR025587A1 (es) *	1999-09-13	2002-12-04	Hoffmann La Roche	Formulaciones en dispersion que contienen inhibidores de lipasa
ATE428733T1 (de)	2000-03-14	2009-05-15	Unilever Nv	Variabele domänen der schweren kette eines antikörpers gegen menschliche ernährungslipasen und deren verwendungen
US7060675B2 (en)	2001-02-15	2006-06-13	Nobex Corporation	Methods of treating diabetes mellitus
US6867183B2 (en)	2001-02-15	2005-03-15	Nobex Corporation	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US6828297B2 (en)	2001-06-04	2004-12-07	Nobex Corporation	Mixtures of insulin drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same
US7196059B2 (en)	2001-09-07	2007-03-27	Biocon Limited	Pharmaceutical compositions of insulin drug-oligomer conjugates and methods of treating diseases therewith
US7053080B2 (en) *	2001-09-21	2006-05-30	Schering Corporation	Methods and therapeutic combinations for the treatment of obesity using sterol absorption inhibitors
WO2003105768A2 (en)	2002-06-13	2003-12-24	Nobex Corporation	Methods of reducing hypoglycemic episodes in the treatment of diabetes mellitus
US9174176B2 (en)	2003-01-09	2015-11-03	Disperse Systems, Inc.	Ultrasonic dispersion apparatus, system, and method
RU2248793C1 (ru) *	2003-11-13	2005-03-27	Лазебник Леонид Борисович	Способ лечения стеатогепатитов
US7510849B2 (en) *	2004-01-29	2009-03-31	Glucolight Corporation	OCT based method for diagnosis and therapy
CN101027318B (zh)	2004-07-19	2016-05-25	比奥孔有限公司	胰岛素-低聚物共轭物，制剂及其用途
US7254429B2 (en)	2004-08-11	2007-08-07	Glucolight Corporation	Method and apparatus for monitoring glucose levels in a biological tissue
US8036727B2 (en)	2004-08-11	2011-10-11	Glt Acquisition Corp.	Methods for noninvasively measuring analyte levels in a subject
JP2008537903A (ja)	2005-04-13	2008-10-02	グルコライト・コーポレーシヨン	Ｏｃｔが基になった血糖モニターのデータ処理および較正方法
US8217025B2 (en) *	2006-11-17	2012-07-10	Harbor Therapeutics, Inc.	Drug screening and treatment methods
ES2350798T3 (es) *	2007-09-12	2011-01-27	Mader S.R.L.	Composiciones farmacéuticas para uso oral para tratar a pacientes afectados por la obesidad.
US20100317642A1 (en) *	2007-10-15	2010-12-16	Inventis Dds Pvt Limited	Pharmaceutical composition of orlistat
US9241908B2 (en)	2007-10-16	2016-01-26	Biocon Limited	Orally administrable solid pharmaceutical composition and a process thereof
US8768423B2 (en)	2008-03-04	2014-07-01	Glt Acquisition Corp.	Multispot monitoring for use in optical coherence tomography
US8309107B2 (en) *	2008-10-06	2012-11-13	Banner Pharmacaps, Inc.	Stable solutions of orlistat for pharmaceutical dosage forms
FR3017536B1 (fr) *	2014-02-18	2017-05-26	Univ La Rochelle	Compositions pour la prevention et/ou le traitement de pathologies liees a l'alpha-glucosidase
JP2019515654A (ja) *	2016-03-16	2019-06-13	ザジェイ．デヴィッドグラッドストーンインスティテューツ	肥満及び／又は糖尿病を処置するための方法及び組成物、並びに候補処置薬剤を識別するための方法及び組成物
US20190022061A1 (en) *	2017-07-21	2019-01-24	Kieu Hoang	Statins (Atorvastatin) can lower blood sugar level in diabetic

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1247547A (en) *	1983-06-22	1988-12-28	Paul Hadvary	Leucine derivatives
CA1328881C (en) *	1984-12-21	1994-04-26	Pierre Barbier	Process for the manufacture of oxetanones
CA1270837A (en) *	1984-12-21	1990-06-26	Hoffmann-La Roche Limited	Oxetanones
CA2035972C (en) *	1990-02-23	2006-07-11	Martin Karpf	Process for the preparation of oxetanones
US5298497A (en) *	1990-05-15	1994-03-29	E. R. Squibb & Sons, Inc.	Method for preventing onset of hypertension employing a cholesterol lowering drug
US5190970A (en) *	1990-10-19	1993-03-02	E. R. Squibb & Sons, Inc.	Method for preventing onset of or treating Type II diabetes employing a cholesterol lowering drug alone or in combination with an ace inhibitor
US5130333A (en) *	1990-10-19	1992-07-14	E. R. Squibb & Sons, Inc.	Method for treating type II diabetes employing a cholesterol lowering drug
US5345056A (en) *	1991-12-12	1994-09-06	Motorola, Inc.	Plasma based soldering by indirect heating
CA2098167C (en) *	1992-06-24	2006-12-19	Dorothea Isler	Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) *	1993-08-05	2007-02-20	Klaus-Dieter Bremer	Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
JP3532999B2 (ja) *	1995-03-24	2004-05-31	株式会社ロッテ	新規なタンニン類およびこれを有効成分とするリパーゼ阻害剤
JPH09227398A (ja) *	1996-02-20	1997-09-02	Zeria Pharmaceut Co Ltd	抗肥満剤
US6004996A (en) *	1997-02-05	1999-12-21	Hoffman-La Roche Inc.	Tetrahydrolipstatin containing compositions
PL191222B1 (pl) *	1997-02-05	2006-03-31	Hoffmann La Roche	Zastosowanie tetrahydrolipstatyny do wytwarzania doustnego farmaceutycznego preparatu do leczenia cukrzycy typu II

1998
- 1998-01-29 PL PL334975A patent/PL191222B1/pl unknown
- 1998-01-29 DK DK98908008T patent/DK1017408T3/da active
- 1998-01-29 AU AU66169/98A patent/AU740375B2/en not_active Expired
- 1998-01-29 CZ CZ19992651A patent/CZ295567B6/cs not_active IP Right Cessation
- 1998-01-29 AT AT98908008T patent/ATE292975T1/de active
- 1998-01-29 RU RU99118887/14A patent/RU2201272C2/ru active
- 1998-01-29 BR BR9807655-8A patent/BR9807655A/pt not_active Application Discontinuation
- 1998-01-29 ME MEP-903/08A patent/ME00578A/xx unknown
- 1998-01-29 KR KR10-1999-7006983A patent/KR100479968B1/ko not_active Expired - Lifetime
- 1998-01-29 CN CNB988023245A patent/CN1154505C/zh not_active Expired - Lifetime
- 1998-01-29 JP JP53371598A patent/JP2001509173A/ja active Pending
- 1998-01-29 PT PT98908008T patent/PT1017408E/pt unknown
- 1998-01-29 TR TR1999/01853T patent/TR199901853T2/xx unknown
- 1998-01-29 NZ NZ336755A patent/NZ336755A/en not_active IP Right Cessation
- 1998-01-29 HU HU0001014A patent/HU230834B1/hu unknown
- 1998-01-29 IL IL13100798A patent/IL131007A0/xx not_active IP Right Cessation
- 1998-01-29 EP EP98908008A patent/EP1017408B1/de not_active Revoked
- 1998-01-29 YU YU34199A patent/YU34199A/sh unknown
- 1998-01-29 DE DE69829763T patent/DE69829763T2/de not_active Expired - Lifetime
- 1998-01-29 CA CA2278854A patent/CA2278854C/en not_active Expired - Lifetime
- 1998-01-29 ZA ZA98753A patent/ZA98753B/xx unknown
- 1998-01-29 ES ES98908008T patent/ES2239799T3/es not_active Expired - Lifetime
- 1998-01-29 WO PCT/EP1998/000468 patent/WO1998034630A1/en not_active Ceased
- 1998-01-29 ID IDW990792A patent/ID22650A/id unknown
- 1998-02-03 AR ARP980100471A patent/AR011106A1/es not_active Application Discontinuation
1999
- 1999-07-30 NO NO19993717A patent/NO324452B1/no not_active IP Right Cessation
- 1999-10-04 US US09/411,554 patent/US6147108A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
NO993717L (no)	1999-10-04
KR100479968B1 (ko)	2005-03-30
ATE292975T1 (de)	2005-04-15
AR011106A1 (es)	2000-08-02
IL131007A0 (en)	2001-01-28
ZA98753B (en)	1998-08-05
HUP0001014A3 (en)	2000-12-28
JP2001509173A (ja)	2001-07-10
CN1246798A (zh)	2000-03-08
DE69829763D1 (de)	2005-05-19
PL191222B1 (pl)	2006-03-31
HU230834B1 (hu)	2018-07-30
HK1025251A1 (en)	2000-11-10
ME00578A (en)	2011-12-20
AU740375B2 (en)	2001-11-01
PL334975A1 (en)	2000-03-27
CA2278854A1 (en)	1998-08-13
BR9807655A (pt)	2000-02-15
EP1017408A1 (de)	2000-07-12
EP1017408B1 (de)	2005-04-13
NO993717D0 (no)	1999-07-30
RU2201272C2 (ru)	2003-03-27
ES2239799T3 (es)	2005-10-01
AU6616998A (en)	1998-08-26
DE69829763T2 (de)	2006-04-13
ID22650A (id)	1999-12-02
DK1017408T3 (da)	2005-08-01
CN1154505C (zh)	2004-06-23
CZ265199A3 (cs)	2000-02-16
PT1017408E (pt)	2005-07-29
HUP0001014A2 (hu)	2000-08-28
KR20000070733A (ko)	2000-11-25
NZ336755A (en)	2001-06-29
WO1998034630A1 (en)	1998-08-13
YU34199A (sh)	2002-08-12
CA2278854C (en)	2014-03-04
US6147108A (en)	2000-11-14
CZ295567B6 (cs)	2005-08-17
TR199901853T2 (xx)	1999-12-21

Legal Events

Date	Code	Title	Description
2018-02-12	MK1K	Patent expired

Publication	Publication Date	Title
AU740375B2 (en)	2001-11-01	Use of gastrointestinal lipase inhibitors
DE69331409T2 (de)	2002-08-29	Oral 1alpha-hydroxyprevitamin d
DE69624699T2 (de)	2003-03-20	Hochdosiertes chromtripicolinat zur behandlung von typ-ii-diabetes
IE66527B1 (en)	1996-01-24	Bilobalide for use as a therapeutic substance
Kamanyi et al.	1994	Hypoglycaemic properties of the aqueous root extract of Morinda lucida (Benth)(Rubiaceae). Studies in the mouse
CA2155009C (en)	2000-04-04	Prevention and treatment of myocardial failure
WO1995017889A1 (en)	1995-07-06	Therapeutic composition for hyperparathyroidism of patient subjected to artificial dialysis
CA2877680A1 (en)	2014-01-03	Use of 2-methylene-19-nor-(20s)-1.alpha., 25-dihydroxyvitamin d3 to treat secondary hyperparathyroidsm
CN120435297A (zh)	2025-08-05	一种用于防治糖尿病及其并发症的人参二醇皂苷组合物及其制备方法和应用
JPH05194209A (ja)	1993-08-03	血管内皮細胞機能改善剤
European Study Group	1992	Efficacy and tolerability of simvastatin and pravastatin in patients with primary hypercholesterolemia (multicountry comparative study)
AU2020298782A1 (en)	2022-01-20	Combination therapy methods, compositions and kits
DE3035494A1 (de)	1981-04-09	Carnitin enthaltendes arzneimittel zur behandlung von hyperlipidaemie und hyperlipoproteinaemie, sowie verwendung von carnitin zur herstellung eines solchen arzneimittels
WO2025212841A1 (en)	2025-10-09	Compositions and methods for treating diseases and disorders associated with muscle weakness
WO2002049636A1 (en)	2002-06-27	An antidiabetic composition of amino acids
JP4355967B2 (ja)	2009-11-04	医薬組成物
RU2747985C1 (ru)	2021-05-18	Твердофазная композиция для коррекции метаболических нарушений при сахарном диабете второго типа
Yadav et al.	2001	Clinical trial of an indgenous compound drug nishaamalki in the management of madhumeha vis-à-vis diabetes mellitus
JP3816545B2 (ja)	2006-08-30	人工透析患者の皮膚そう痒症治療組成物及び副甲状腺機能亢進症治療組成物
MXPA99007163A (en)	2000-04-24	Use of gastrointestinal lipase inhibitors
DE69227089T2 (de)	1999-04-22	Weizen Alpha-Amylase-Inhibitor zur Behandlung von Diabetes
DE102017119313A1 (de)	2019-02-28	Gallensäure enthaltendes appetitzügelndes Mittel
HK1025251B (en)	2004-11-12	Use of gastrointestinal lipase inhibitors
EP1023059B1 (de)	2005-12-21	Pharmazeutische zubereitungen
CN108066373A (zh)	2018-05-25	一种防治2型糖尿病的药物及制备方法